Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET

Company Participants

Joshua Higa - Head of Investor Relations

Emil Kakkis - Founder, President and Chief Executive Officer

Erik Harris - Executive Vice President and Chief Commercial Officer

Mardi Dier - Executive Vice President and Chief Financial Officer

Camille Bedrosian - Executive Vice President and Chief Medical Officer

Conference Call Participants

Gena Wang - Barclays

Joori Park - SVB Securities LLC

Christopher Raymond - Piper Sandler

Tazeen Ahmad - Bank of America Merrill Lynch

Dae Gon Ha - Stifel

Maurice Raycroft - Jefferies LLC

Yigal Nochomovitz - Citigroup Inc.

Joon Lee - Truist Securities

Yaron Werber - Cowen and Company, LLC

Elizabeth Webster - Goldman Sachs Group, Inc.

Joel Beatty - Robert W. Baird & Company, Inc.

Liisa Bayko - Evercore ISI

Operator

Thank you for standing by. Good afternoon, and welcome to the Ultragenyx Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have the opportunity to ask questions during the Question-and-Answer portion of the call.

It is now my pleasure to turn the call over to Joshua Higa, Executive Director and Head of Investor Relations.

Joshua Higa

Thank you. We issued a press release detailing our financial results, which you can find on our website at ultragenyx.com.

Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Mardi Dier, Chief Financial Officer; and Camille Bedrosian, Chief Medical Officer.

I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.

I'll now turn the call over to Emil.

Emil Kakkis

Thanks, Josh, and good afternoon, everyone. 2022 has been a year focused on execution for our team both commercially and in our pipeline. We have made substantive progress across our key priorities and in issues despite ongoing macroeconomic challenges. In the third quarter, we continue to achieve strong year-over-year growth from our commercial programs and continue to broaden our commercial revenue base.

In Latin America, we are seeing positive commercial and regulatory momentum across multiple countries with increasing revenue. In Europe, our launch of Evkeeza is underway and we are seeing significant enthusiasm from lipid experts on the potential for Evkeeza to change the treatment paradigm. We've submitted already or will submit reimbursement dossiers in multiple countries and are beginning country-specific pricing discussions. We believe the enthusiasm of lipid expert for the product will help in supporting effective reimbursement discussions.